Agastiya Biotech

General Information

Company Name

Agastiya Biotech

Founded Year

2019

Location (Offices)

Carlsbad, United States +1

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Health Care, Pharmaceutical

Funding Stage

Social Media

Agastiya Biotech - Company Profile

Agastiya Biotech is a clinical stage oncology drug development company utilizing AI:Intuit-Serendipity, an AI platform invented by Dr. Pillai, founder of Agastiya Biotech. The company's flagship molecule, AB001, has undergone Phase I trials in India, with Phase II scheduled for October 2024 in 30 centers across India. Additionally, Agastiya Biotech has completed preclinical work for a KRAS inhibitor and a molecule for diabetes. Founded in 2019, the company operates in the Biotechnology, Health Care, and Pharmaceutical industries, with a mission to produce medicines in India for equitable access. The company's headquarters and last investment details are not specified. As of now, they have not disclosed their last investment and the associated investors. Agastiya Biotech's slogan, "Innovating highly efficacious, toxicity-free small molecules for metastasized cancers," reflects its commitment to developing innovative treatments for cancer.

Taxonomy: oncology drug development, clinical stage trials, cancer research, molecular formulations, therapeutics, cancer stem cells, tumor suppressor genes, oncogene mutations, small molecule development, SARS-CoV-2 therapeutics, pharmaceutical innovation, equitable access, patented formulations